Simple Summary Advances in molecular genetics have radically changed all aspects of
cancer prevention, screening and treatment and, today, women who are suspected of being …

Background Our study aimed to establish 'real-world'performance and cost-effectiveness of
ovarian cancer (OC) surveillance in women with pathogenic germline BRCA1/2 variants …

Women at risk for hereditary breast and ovarian cancer syndromes are frequently seen in
primary care and gynecology clinics. They present with a distinctive set of clinical and …

Simple Summary Identifying BRCA mutations carriers reduces cancer incidence by
surveillance and prevention. We analyzed the cost-effectiveness of population screening …

Simple Summary Being a healthy carrier of a BRCA1/2 pathogenetic variant is not a
contraindication to hormonal contraception and menopause hormonal therapy; however …

Objective BRCA1 and BRCA2 mutation carriers are recommended to undergo risk-reducing
salpingo-oophorectomy (RRSO) by age 40 and 45, respectively. However, the carriers have …

Current approach to identify BRCA 1/2 carriers in the general population is ineffective as
most of the carriers remain undiagnosed. Radiomics is an emerging tool for large scale …

To determine the impact of the coverage of risk-reducing salpingo-oophorectomy (RRSO)
and mastectomy (RRM) as well as genetic testing for BRCA pathogenic variants by the …

In November 2022, the findings of the Avoiding Late Diagnosis of Ovarian cancer (ALDO)
study were published. Subsequent media coverage suggested that investigators had found …

Objective The real-world management of patients with non-BRCA, homologous
recombination repair pathway variants with increased or uncertain risks of ovarian cancer is …